Side-by-side · Research reference
AdipotidevsHGH Fragment 176-191
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BAnimal-StrongHUMAN-REVIEWED28/59 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
01Mechanism of Action
Parameter
Adipotide
HGH Fragment 176-191
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
N/A — does not interact with GH/IGF-1 axis
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Antibody development
—
Not reported in available studies
02Dosage Protocols
Parameter
Adipotide
HGH Fragment 176-191
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
—
Frequency
Not specified in available data
Once daily (animal models)
Evidence basis
Preclinical animal models only
Animal studies only
Human data
None — no clinical trials reported
—
Animal dose (IP)
—
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
Human equivalent dose
—
Not established — no published human RCTs
Detection window
—
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
Oral bioavailability
—
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
HGH Fragment 176-191
Primary fat target
White adipose tissue (all depots)
Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
Weight gain reduction
—
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
Body fat reduction
—
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
Lipolytic activity
—
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
Insulin sensitivity
—
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
IGF-1 impact
—
No elevation — fragment does not activate GH/IGF-1 axis
Beta-3 AR dependency
—
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
Human evidence
—
None published — pre-clinical only
04Side Effects & Safety
Parameter
Adipotide
HGH Fragment 176-191
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Human safety data
—
Not available — no published human trials
Metabolic profile
—
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
05Administration Protocol
Parameter
Adipotide
HGH Fragment 176-191
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
Animal protocols: 14–19 days. Human duration not established — no published trials.
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
5. Detection
—
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015